Jean-Pierre Sommadossi has spent his career battling viruses. He has built and lead companies that have successfully tackled hepatitis C, B, and HIV/AIDS, creating landmark therapeutics along the way. He is committed to world-class science, has authored over 150 papers, and holds over sixty patents. Atea is a biopharmaceutical company discovering and developing best-in-class therapies to address life-threatening viral diseases. In March 2020, the company pivoted all its efforts to develop an oral direct acting antiviral therapy for COVID-19.
